Drugs / bictegravir/emtricitabine/tenofovir alafenamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03502005 | Mar 2018 → Dec 2019 | HIV infectious disease | Midland Research Group, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bictegravir/emtricitabine/tenofovir alafenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03502005 ↗ |